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Kallhm-l\lcicr pcr«nl SU""'i\'lll eurvu_ DCT-TVAJ1"~4aArj
b I", mice were injocted at birt!l with the l\'RASQlitR and ere
vinlses Indicated. Dashed !inc: Cre alOlle " - 20 and NRAS
alone /I - IS. Black line: NRASQ6IR and ere vinlScs in
combination II"" 22. Blue li,lC: TRE-NRAS-IRES-Cre and lb-
off" ~.:I6. Red line: NRAS-IRES-Crc (u - 8), The comparison
between the solid lines and the dashed line (controls) was
highly signiticanl (1''''0.008) demonstrating that both Cre and
NRAS are required for l\llllor fomlatiol1 in this COlltC.~t.
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Intluetion of melanoma in DCT_TIiAlilrk4u1."r/ ((I.-dlrll'
mice. Mire were injected with NRASQ6JR and ere viruses
at birth. (A) A represclllati\'e 1llQUSC (age 42 d.:lyS) with a
tumor at the site of injection. (B-C) H&E stained tumor
sections. (D) lHC for RAS. (E) 11K for phosphorylated Erk
(p-Erk) (F) lHC for phosphorylated p70 56 kin,asc (II-S6K).
(G) 11K for Ki67. (II) lHC for SIOO. All sections were
cOllnterslained with hl'1l1,atoxylin. Scale bars represent 1.0
mm forlB) and 200flm for (C-H).
,,'uture Direelions
·Preservation and evaluation ofsamples to ide11lify Ihe mct:hanism(s) ofrcsistance to either genetic or phannacological inhibition of the MAPK
pathway.
-E"alualiol1 ofresistallttumor samples to el1sure supprcssionohiraHy delivered NRAS expression by both IHC ofFFPE tissue and by Western btot
analysis frol11 established eetl lines.
'Gcne expression analysis to identify novel mechanisms that may be responsible for resiSlance in this context using GClleChip 12X 135k
microarrnys
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Prolei" upns.ion in ul,lanlrd melRnoma ~ells. E.~pression of NR....SV"'~·HA from an e.~pI8med lumor umple deri,·cd from a DCT·TVAII"k.Ja Arflw<·" mouse
injl'Cled "itn TRE-NRAS-IRES-Cre and TeJ-offviruses. 1l>e cells "ere wown in the absence H 01 presence (+) of D<.>x for 1 "'00;; NRAS expression was detected
wilh a pan·RAS anllbody. The villllly delivered NRi\S is larger than endogenous RA5 due 10 the HA epitope Illg on NRAS The blots were re-probcd With an
amibody thaI re<:oS"izes a-rubulin .. B loading conlro1, Kilplnn.;'leier per~rllt lun'Ival elln·es. DCT_TVNIJ'k.JuArjfox {(IX mice W\.'fC inje<:t\.'<1 al birth "ith TRE·
NRAS·IRES-erc and Tet.off, D.s/led line Tumor·b.ming mice wcre treated "ith Dox "hell tumors reached 1,000 mm3 /I. 12 Black line umreated,,· 33 1l>e
comparison bet\\~en the two groups was hil!hly significant (I'. 1.29 x 10·7) demon51rating thllt inhibition of NRAS c.xpressioo in this context signiticantly increases
sUIVi".1 Complrisoll or primo')' and rr.<islant IIIlIIOn. Tumors were induced in DCT-TVAII"k.JaArjJox fi"r mice b)' delivery ofviru!iC5 containing TRE-NRA5-
IRES-Cre and Tet-off. Top Panel Representatl"e H&E. l\'RAS-HA 111C_ and P-EI1.: me of a primary tumor Bottom Panel Representative 11&E, NRAS-IIA IItC,
and I'-EI1.: tHC ofa tumor that b«ame f~~tanl "hileoo Dox treatment. As c.~pecJed, virally delivered NRAS-HAexprco;§ioo was detected in the primary tumor but
IlOt in Ihe l'C$islam Do~ Irtaled tum~.
Rcsuhs and Conclusions
'Both /NK./a andARF, ocr-TVA mice were croSSl."d to IIIk4aAljfal/nll11ice to generate DCT·TVA;IIIUa At/lox fal mice.
'No tumors were detected in TVA'l1cgative mice but in 12 weeks. more th1m one-third ofOCT-TVA:/uk.Ja Arjlv.llox mice developed mel!1Il01l1a that
was histologicalty simi[arto the human disease.
·Delivery ofa dms in which NJlASQ611? and ere ellpression was linked by an intemal ribosomal entl)' site (IRES) resulted in tumor fomlatlon in
nearly two-thirds ofTVA positi"e mice. Shorlten" eUllllreS Ii'om the primary tumors were established and were syngeneic with the OCT-
TVAlilJk.Jo AJjw.T lax strain, fonnlng twnors in all recipient mice
·In the contcxt ofTel-on, the Tet-responsive gene is only expressed in the presence of doxycycline (DOli): in the context ofTet-off. the Tet-respollsi"e
gene is repressed in the presenceofDo.~. Using this approoch in the context ofTet·o!T:md the TRE-NRA5·1RES-Crevcctor "eobscryed tumor
fonn.1tion in 72% ofDCT-TVAlIIiNa ArjlQX lox mice
-In contrast to tumors fro11l1l1ice not ellposedto Ooll, rcsistlmtlumors from Dox treated mi<.:e 1:1Ckcd ellogenous NRAS expressiou indicating thm
tigltl Oox-mctliated NRAS regulation remained intact. Bee.1use reactivation of the MAPK pathway is one possible mcchanism of resistance. we used
IHC to detect active phospholylated Erk (P·Erk) in the resistant Ulmo!"S. In COlllmst to the primary tumors. very lin Ie P-Erk e.~pression was detected
in the resistant tUIllO!"S
·nlcse rCSlllls su!!.!!eSl that reactinuiOll ofth!: MAPK pathway upstream ofErk is not the mechanism of resistance. Se"cral other mechanisms of
resistance are possible. including activation ofaltemati\'esignalingp;lthways.
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~plpn-/llcitrperccnlsu",,'i\·1lIcu""'C.f\1l1l1icewere
injc<:ted with NHASQ6iR and Cit' viroses at bi"h. For
DCT-TVAnegatl"e1l1lcen'" 16 (dashed line) and for
DCr-TVA-positi"e mice" = 22 (solid line).
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RCAsrrVA Melanoma Mouse Model System
TVA: roceptor for subgroup l\ Avian Lcukosis Virus (ALV-/\)
-Confers susceptibility toALV·A infl'Clion whell introduced into rells >lonnall)' resista.t1to infoction, can be expressed
ina tissue-sjX.'Cific nHmner allowing effieicnt gene targcting
·RCAS; r\.'Plication competent retrovira[ vector (in a"ian cells), deri\'ed from ALV
'[n replicating mammalian cells expressing TVA. RCAS can ~tably imcgrate into the DNl\ and express the insened gem: at
high levels
·Replication defecti\'c in m31l1lnalian cells: does not spread in target animals. Multiple oncogenic alterations call be
introduced into the same celt orallimal withol1l the cost Of1!r11eratin1! 1l1uhiple strninsoftransgenic mice
·NOrlldogcllolls\·iral scquenceswith which thesc ,'e<:tors could recol11biue
·GC'nec.~J1Tession can be reduced by RNAi usingamiRNAexpressing 'l;I"",========="
. ~--
E:lllression of RJ\S in 1)6-I\IELcells lind growlh in 50ft a\:ar. Ccll1YSlltcs from uninfectcd D6-MEL mclanocytes (-) or
cells il&-ctcd with retroviruses containinll either Q61 R NRAS or V12 KRAS (+) were collected in SDS lysis buffer. separated
on a 4-20% gradient1!e1 and illl1l1lmoblottcd for total RAS expression (a-RAS). IICtivaTed IIhOsphol)'lated ERK p44/42 (a-
pERKII2). total ERK ]>44/42 expression (a.-·[otal ERKIJ2), and a-tubulin.
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Kailian-Mciu Ilcr<:('.111 survi,'al cur\'e. DCT-TVAlIl!k-l<lArf""'I,,,,, mice were injocted subcutaneously with a cell line derived from an
explamed melanoma: 5 x 106 eellsll- 10 (large dashed line} and Ix 107cells II "" 7 (solid line). Ix 107 cells that had bc~l passaged m ,'jm
were re-injct:t\.-d ,,- 17 (small dashed line), Protein e~pressiOIl in CXIII'Ilued melanoma «lis. Expression of NRA5Qf>IIl,.HA from eight
different micc (54, 286. 287. 360A, 360B. 332,333,335 and 336). The A and B designation indicates two scpamte tumors from the same
mouse. ExpressiOll was detected with an antibod)' to the HA epitope tag on NRAS. D6-MEL immonal melanocytes were used lIS a negative
control for HA expression and !lonnal mouse astrocytes were used as a positive control for pl9 Arf expression. 111e blots weTC re-probed
with a-tubuJinasa loadingeontrol.
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Initial Validation of Melanoma Associated Genes
00
n .....
moIO~.:'=1 ,%:",,;;.,.
'-~
-=y:::..
I u_._...._
ftmoJAO"._.., 1YfO.'.m8_l
•lolo:,.,..,.,
_I
Ink4a/Arflocus
"""
Molecular Analysis of Human Melanoma'
Gent/Locus Fllmililll(FllSnoradiclS) Alterations
9p21 :pJ6INh:~'1)19ARF F, S Point mutation,delelioll, promoter,\!
p53 S I)oinl mutation
p27 S Decreased tlpression
IOq23: PTEN S LOH and Poin' mutation
Ilq22-2J S lOU
NRAS S Poinl mutation
C-myc S On~rexpression
B.RAF S I)oinl ~lulalion
i\'ICI R r...luoc<>r1i11 ,,,."pl0'f S Point mutation
",'dallied from Caslellano and I'armillni ~lelanomllResearch 1999:9:421-432
Schematic of the canonical RAS effector pathways RAF-MEK-
ERK and PI3K-Akt and the mutations that most often activate
these pathways in melanoma patients
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Melanoma is the most rapidly
increasing malignancy among
young people in the U.S.
·The incidence of melanoma has increased by Illorc
than 600 percent over the last forty years
(ACS statistics www.cancer.om)
·Melanoma is the leading cause of cancer death in
women aged 25-29
·5-)'r survival for advanced stages of the disease is <20%
